Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 91.0%

Neg 0% Neu 0% Pos 91%

Wedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the price target from $15 to $22.